Company Description
Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer.
The company’s lead radiotherapeutic candidate is REYOBIQ, a patented radiotherapy for patients with central nervous system and other cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers.
It also develops Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere to treat various solid organ cancers, such as primary and secondary liver cancers by intra-arterial injection.
In addition, it develops and commercializes laboratory-developed tests, such as the CNSide Test to identify tumor cells that have metastasized to the central nervous system in patients with carcinomas and melanomas.
The company was formerly known as Cytori Therapeutics, Inc. and changed its name to Plus Therapeutics, Inc. in July 2019.
Plus Therapeutics, Inc. was founded in 1996 and is headquartered in Houston, Texas.
| Country | United States |
| Founded | 1996 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 21 |
| CEO | Marc Hedrick |
Contact Details
Address: 2710 Reed Road, Suite 160 Houston, Texas 77051 United States | |
| Phone | 737 255 7194 |
| Website | plustherapeutics.com |
Stock Details
| Ticker Symbol | PSTV |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001095981 |
| CUSIP Number | 72941H400 |
| ISIN Number | US72941H5090 |
| Employer ID | 33-0827593 |
| SIC Code | 3841 |
Key Executives
| Name | Position |
|---|---|
| Dr. Marc H. Hedrick M.B.A., M.D. | President, Chief Executive Officer and Director |
| Andrew J. Sims CPA | Vice President of Finance and Chief Financial Officer |
| Dr. Michael Stanley Rosol Ph.D. | Chief Development Officer |
| Desiree Smith | Corporate Controller |
| Russell W. Bradley | President and GM of CNSide Diagnostics |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jul 21, 2025 | ARS | Filing |
| Jul 21, 2025 | DEF 14A | Other definitive proxy statements |
| Jul 18, 2025 | 8-K | Current Report |
| Jul 11, 2025 | PRE 14A | Other preliminary proxy statements |
| Jun 25, 2025 | SCHEDULE 13G/A | Filing |
| Jun 23, 2025 | EFFECT | Notice of Effectiveness |
| Jun 23, 2025 | RW | Filing |
| Jun 23, 2025 | 424B3 | Prospectus |
| Jun 20, 2025 | 8-K | Current Report |
| Jun 20, 2025 | S-1/A | [Amend] General form for registration of securities under the Securities Act of 1933 |